MX387267B - Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico. - Google Patents

Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.

Info

Publication number
MX387267B
MX387267B MX2018000175A MX2018000175A MX387267B MX 387267 B MX387267 B MX 387267B MX 2018000175 A MX2018000175 A MX 2018000175A MX 2018000175 A MX2018000175 A MX 2018000175A MX 387267 B MX387267 B MX 387267B
Authority
MX
Mexico
Prior art keywords
carbonic anhydrase
therapeutic use
anhydrase inhibitors
arylsulfonamide compounds
compounds
Prior art date
Application number
MX2018000175A
Other languages
English (en)
Spanish (es)
Other versions
MX2018000175A (es
Inventor
Zaihui Zhang
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of MX2018000175A publication Critical patent/MX2018000175A/es
Publication of MX387267B publication Critical patent/MX387267B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018000175A 2015-07-01 2016-07-01 Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico. MX387267B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187636P 2015-07-01 2015-07-01
PCT/US2016/040736 WO2017004543A1 (en) 2015-07-01 2016-07-01 Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use

Publications (2)

Publication Number Publication Date
MX2018000175A MX2018000175A (es) 2018-03-26
MX387267B true MX387267B (es) 2025-03-18

Family

ID=56411955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000175A MX387267B (es) 2015-07-01 2016-07-01 Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.

Country Status (11)

Country Link
US (1) US10562859B2 (enExample)
EP (1) EP3317255B1 (enExample)
JP (1) JP6795525B2 (enExample)
KR (1) KR102637759B1 (enExample)
CN (1) CN107922345B (enExample)
AU (1) AU2016287587B2 (enExample)
BR (1) BR112018000065B1 (enExample)
CA (1) CA2991168C (enExample)
IL (1) IL256527B (enExample)
MX (1) MX387267B (enExample)
WO (1) WO2017004543A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3606928T1 (sl) * 2017-04-05 2023-02-28 President And Fellows Of Harvard College Makrociklična spojina in njene uporabe
KR20210000564A (ko) 2019-06-25 2021-01-05 공주대학교 산학협력단 신규 아만타딘 유도체 화합물 및 이의 용도
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途
EP4161910B1 (en) * 2020-06-02 2025-01-08 Yeditepe Universitesi 2-(3-(2-methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide and derivatives as inhibitor of carbonic anhydrase ix for the treatment of cancer
TR202014185A2 (tr) * 2020-09-08 2022-03-21 Anadolu Ueniversitesi BAZI YENİ 4-(2-((5-(SÜBSTİTÜEAMİNO)-1,3,4-TİYADİAZOL-2-İL)TİYO)ASETİL)BENZENSÜLFONAMİD TÜREVLERİ ve SÖZ KONUSU TÜREVLERİN SENTEZİ İÇİN BİR YÖNTEM

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
EA200900821A1 (ru) * 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
CN103221388B (zh) 2010-07-09 2016-09-28 维理生物技术公司 用于抑制转移性肿瘤生长的新型磺酰胺化合物
WO2013023274A1 (en) * 2011-08-16 2013-02-21 Universite Laval Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer

Also Published As

Publication number Publication date
KR20180023990A (ko) 2018-03-07
CN107922345A (zh) 2018-04-17
EP3317255A1 (en) 2018-05-09
KR102637759B1 (ko) 2024-02-19
JP6795525B2 (ja) 2020-12-02
BR112018000065B1 (pt) 2023-11-07
CN107922345B (zh) 2021-03-23
AU2016287587A1 (en) 2018-01-25
EP3317255B1 (en) 2021-09-01
AU2016287587B2 (en) 2020-04-30
CA2991168C (en) 2022-04-26
IL256527B (en) 2021-04-29
US20180201584A1 (en) 2018-07-19
BR112018000065A2 (pt) 2018-09-11
IL256527A (en) 2018-02-28
JP2018519332A (ja) 2018-07-19
US10562859B2 (en) 2020-02-18
HK1248228A1 (en) 2018-10-12
MX2018000175A (es) 2018-03-26
WO2017004543A1 (en) 2017-01-05
CA2991168A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX374439B (es) Compuesto de piridona como inhibidor de c-met
EA201891211A1 (ru) Ингибиторы cxcr2
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CR20150462A (es) Inhibidores de erk y sus usos
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
CR20150524A (es) Compuestos de heteroarilo y sus usos
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2015012490A (es) Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201692521A1 (ru) Пиразольные соединения и их применение в качестве блокаторов кальциевых каналов т-типа
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
EA201691177A1 (ru) Ингибиторы серин/треонинкиназ
EA201500931A1 (ru) Производные пиридин-4-ила
EA201592183A1 (ru) Ингибиторы bace
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ